CS
IPSC icon

Credit Suisse’s Century Therapeutics IPSC Stock Holding History

Credit Suisse’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$5 – 3505
2022
Q4 		$5 Sell
1
-111
-99% -$1.05K ﹤0.01% 3820
2022
Q3 		$1K Buy
112
+93
+489% +$979 ﹤0.01% 3866
2022
Q2 		$0 Buy
+19
New +$186 ﹤0.01% 4117

Other funds holding IPSC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse's IPSC Position: Q1 2023 in Review

Credit Suisse sold out of Century Therapeutics (IPSC) in Q1 2023, closing a stake of 1 share — an estimated $5 sold.

Credit Suisse first reported a position in IPSC in Q2 2022 and held it in 3 quarters. The position peaked at $1K in Q3 2022. 63 funds tracked by Wall St. Rank hold IPSC as of Q1 2023.

  • Credit Suisse reported no remaining Century Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 1 Century Therapeutics share in Q1 2023, an estimated $5.
  • Credit Suisse first reported a position in Century Therapeutics in Q2 2022 and held it in 3 quarters.
  • Credit Suisse's Century Therapeutics position peaked at $1K in Q3 2022.
  • 63 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.